Fact CheckerSign in

NCT07232459Recruiting

[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis

Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis

Source: ClinicalTrials.gov · Last updated 8 Sept 2026

Brief summary (registry, in English)

\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \[18F\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \[18F\]FT8 PET imaging in human subjects.

Status (registry)
Recruiting
Study type
Observational
Enrollment
25 (estimated)
First submitted
13 Nov 2025
Start date
21 Jul 2025
Primary completion date
20 Jul 2028
Lead sponsor
Tianjin Medical University
Diseases
Amyloidosis
NCT number
NCT07232459

What you commit to

  • Study type: Observational
  • Planned participants: 25
  • From 21 Jul 2025 to the primary completion date, 20 Jul 2028
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Subject Recruitment Participants will be recruited from outpatients and/or inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers.
  • Amyloidosis Patients:
    • 2.1 Inclusion Criteria:
    • Subjects must meet all of the following criteria:
  • Adult patients (age ≥ 18 years);
  • Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis.
  • Scheduled to undergo a clinical Pan-Amyloid PET/CT scan as part of standard care or clinical evaluation.
  • Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria
    • Subjects will be excluded based on any of the following:
  • Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation.
  • Pregnancy or breastfeeding.
  • Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up.
    • 3\. Healthy Volunteers: 3.1 Inclusion Criteria:
    • Subjects must meet all of the following criteria:
  • Adult subjects (age ≥ 18 years);
  • No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG).
  • Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria:
    • Subjects will be excluded based on any of the following:
  • History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder.
  • Pregnancy or breastfeeding.
  • Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The First Affiliated Hospital of University of Science and Technology of China
Coordinator of this site? Confirm its status
HefeiChinaRecruiting
The Affiliated Hospital of Qingdao University
Coordinator of this site? Confirm its status
QingdaoChinaRecruiting
Tianjin Medical University General Hospital
Coordinator of this site? Confirm its status
TianjinChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.